TEAEs THROUGH
52-WEEK STUDY PERIOD

This table shows the common TEAEs occurring in ≥2% of patients through week 52 of the study.
This table shows the common TEAEs occurring in ≥2% of patients through week 52 of the study.

OPZELURA is for short-term and non-continuous chronic use only.2

*Includes patients who received ≥1 dose of OPZELURA in the vehicle-controlled and/or extension periods.1

TEAE=treatment-emergent adverse event.

Safety profile through 52 weeks inclusive of 8-week vehicle control and long-term extension periods1
  • Safety data from the 44-week extension study are not included in the Prescribing Information for OPZELURA
  • No conclusions of efficacy or safety should be made based on these results

*Includes patients who received ≥1 dose of OPZELURA in the vehicle-controlled and/or extension periods.1

TEAE=treatment-emergent adverse event.

See 52-week disease control data >

References: 1. Papp K, Szepietowski JC, Kircik L, et al. Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: results from two phase 3 studies. Presented at: Revolutionizing Atopic Dermatitis Virtual Conference; June 13, 2021. 2. Opzelura. Prescribing Information. Incyte Corporation; 2022.